Connect with us

Technology

Amavita Heart and Vascular Health Achieves Two Prestigious IAOCR Certifications

Published

on

MIAMI, May 8, 2025 /PRNewswire/ — Amavita Heart and Vascular Research Services LLC the research arm of Amavita Heart and Vascular HealthTM, a leading clinical research organization, is proud to announce it has successfully achieved the GCSA Global Quality Standard for Clinical Research Sites. This milestone certification follows the recent success of Amavita’s Principal Investigator, Dr. Pedro Martinez Clark, who recently achieved the QM-IAOCR Internationally Qualified Clinical Research Investigator Accreditation standard. This further reinforces the organization’s commitment to operating at the highest international standards. 

To secure both quality standards, Amavita Research has undergone a rigorous evidence-based assessment of their site’s business operational processes that underpin the delivery of world-class clinical trials for GCSA and for the individual staff accreditation, robust assessment of the core role-specific competencies for Clinical Research Investigators. This achievement underscores Amavita Research’s dedication to embedding and maintaining best practices in clinical trial management, patient safety, and regulatory compliance. This joint achievement provides reassurance to sponsors, CROs, staff and ultimately the patients, that trial sites have been independently assessed against robust global quality standards and that research is in safe hands. It also provides a solid platform for Amavita Research’s continued growth, based on the solid foundations of independently quality assured best-practice processes. 

“We are thrilled to receive the GCSA site certification, which is a testament to our team’s dedication to conducting clinical trials with the highest standards of quality and integrity,” explains Pedro Martinez-Clark, founder and medical director at Amavita Research. “This achievement not only validates our efforts but also enhances the confidence and trust of our sponsors and participants in the research we conduct and positions us as a research center of excellence in the cardiovascular field.” 

The GCSA Certification is the world’s only internationally recognised quality standard and certification developed specifically for clinical trial sites. It recognizes sites that have demonstrated excellence across the critical business operational areas that underpin the delivery of world-class patient and sponsor experiences across the end-to-end clinical trials pathway. By meeting the specific criteria across seven key areas – ranging from feasibility and study start-up to patient engagement and governance — Amavita Research has demonstrated its ability to provide the highest quality and efficiency in clinical research. 

“Amavita Research are a professional team, and it is clear from working with them through the GCSA certification that they have implemented a suite of clear working processes to support the efficient and successful running of their clinical trials,” summarizes Colette Donaghy, director of and assessment, IAOCR and GCSA.  

Both IAOCR and GCSA use comprehensive assessment frameworks that have been developed with and ratified by Industry experts. The GCSA Global Quality Standard for Clinical Research Sites was developed with the support of a Global Advisory Board of key stakeholders and experts from across the industry. IAOCR’s accreditation standards for clinical research professionals are built with international taskforces with role-specific subject-matter experts. In addition to the IAOCR Investigator Accreditation, all seven areas of the GCSA quality standard were met which included: Feasibility; Study Start-up & Initiation; Patient Engagement; Study Management, Operations & Close Down; Governance; Site Business Strategy and Workforce Quality.

Whilst clinical research is a highly regulated industry, until recently with the introduction of GCSA, there have been no established standards by which sites can demonstrate that they are able to meet the expectations of sponsors, CROs and patients, and no way for sponsors or CROs to select clinical research sites based on clear quality standards which have been independently assessed at the organizational level. GCSA sets this much-needed industry standard for research sites to strive for and achieve; it allows sites to evidence and communicate their capabilities and differentiate in a crowded and increasingly competitive marketplace. Beyond the assessment and certification process, where required, GCSA will deliver individual, practical support on the areas for development to meet the standards and will work collaboratively with sites to achieve certification.  

About IAOCR

IAOCR is The International Accrediting Organization for Clinical Research. We are the only organization in the world to accredit Clinical Research Professionals to international standards. Through robustly verifying competence, IAOCR reduces risk to patients, clinical research and reputations – whilst improving compliance and bringing valuable new treatments to market more quickly and safely.

IAOCR competence verification, process assessment and accreditations have been built specifically for the clinical research industry in collaboration with industry experts globally. They provide quality standards and visible professional certification marks to companies, charities and public health organizations that are committed to globally consistent and high-quality clinical research.

We believe that clinical trial patients anywhere in the world deserve the best protection in terms of rights and wellbeing. Therefore, in addition to providing accreditation, training and consultancy services, IAOCR works with industry leaders and regulators around the globe to raise standards and improve the clinical research landscape. To find out more visit: iaocr.com

About GCSA
GCSA is a global quality standard for clinical trial sites set across seven key areas. It ensures clinical trial sites are working to robust and effective business operational processes across the end-to end clinical trial pathway, so that they can deliver best-in-class services to patients and sponsors/CROs. The GCSA framework was developed over 4 years with industry research and engagement. It has been ratified by a Global Advisory Board of leading industry representatives from the not-for-profit and commercial sector, including leading global Sponsors and CROs, the NHS and other leading healthcare organizations.

The standard has been built to address key industry challenges and facilitate synergistic working between sites and sponsors to enable better patient outcomes. It provides potential sponsors with an assurance of capability through passing independent assessment based on standards and expectations specified by sponsors. Furthermore, GCSA aims to increase clinical research through alignment with commercial requirements. To find out more visit: iaocr.com

View original content:https://www.prnewswire.com/news-releases/amavita-heart-and-vascular-health-achieves-two-prestigious-iaocr-certifications-302448742.html

SOURCE Amavita Heart & Vascular Health

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS

Published

on

By

With the presence of Emmanuel Macron and Narendra Modi, Prime Minister of India

PARIS, June 20, 2026 /CNW/ — From June 17 to 20, 2026 at Paris Porte de Versailles, VivaTech celebrated its 10th edition, surpassing the exceptional milestone of 200,000 visitors from 165 nationalities, with more than 15,000 startups present, 1,155 speakers and over 5 billion cumulative impressions on social media. Europe’s largest tech and innovation event has reached a new dimension, consolidating its status as an unmissable global gathering.

Exceptional speakers

VivaTech welcomed the greatest figures in global tech: Jeff Bezos (Amazon & Blue Origin), Dave Limp (Blue Origin), Bernard Arnault (LVMH), Henna Virkkunen (European Commission), Ekaterina Zaharieva (European Commission). Germany, Country of the Year 2026, was represented by a ministerial delegation, while India, AI Country Partner 2026, was led by Prime Minister Narendra Modi, as a continuation of the AI Summit in New Delhi.

Innovation and business at the heart of the event

More than 4,500 exhibitors, 61% of whom were international, showcased their latest innovations. Among the standout innovations: the smart contact lens by XPANCEO, the thought-controlled humanoid robot by Unitree x HABS, and the 3D-printed resorbable implants by Lattice Medical. New formats such as the Business Plaza and Investors Office Hours further accelerated business connections.

The VivaTech x Bloomberg Awards

For the first time, VivaTech presented the VivaTech x Bloomberg Awards, recognising the most influential figures in global tech, including Sir Tim Berners-Lee (Visionary Award), Joe Tsai (Leadership Award) and Yann LeCun (Momentum Award).

Innovation open to all

VivaTech also took over the Champs-Élysées on June 14th for an open-air technology showcase, before opening its doors to the general public on June 20th with astronaut Thomas Pesquet as guest star.

“This 10th edition was not a celebration of the 9 previous years, but the opening of a new decade full of promise.” — Maurice Lévy, Michèle Benbunan & François Bitouzet, VivaTech

See you from June 16 to 19, 2027 at Paris Expo Porte de Versailles for VivaTech 2027!

About VivaTech

VivaTech accelerates innovation by connecting startups, tech leaders, major companies, and investors responding to our world’s biggest challenges.  

Each year, over four exciting days in Paris, VivaTech creates Europe’s biggest startup and tech event, exploring the most disruptive topics in tech with world-premiere demos, launches, and conferences in a collaborative ecosystem. This is where business meets innovation. Join us for the eleventh edition of VivaTech 16-19 June 2027.

For more information go to our website at https://vivatech.com/media or follow us on social media @VivaTech.

Contact
press@vivatechnology.com 

Logo: https://mmx.prnewswire.com/media/MS1865564/VT_LOGO_EN.jpg
Photo : https://mmx.prnewswire.com/media/MS1869778/VivaTech_2026.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/vivatech-2026-celebrates-its-10th-anniversary-with-a-record-edition-surpassing-200-000-visitors-302805827.html

SOURCE VivaTech

Continue Reading

Technology

Pope Leo XIV embraces paediatric patients at CNAO in Pavia

Published

on

By

PAVIA, Italy, June 20, 2026 /PRNewswire/ — The National Center for Oncological Hadrontherapy (CNAO) served as the first stop today during Pope Leo XIV’s pastoral visit to the city of Pavia. His choice to begin his journey at this center reflects a profound commitment to fostering meaningful dialogue between advanced scientific progress and the alleviation of human suffering.

CNAO President Gianluca Vago and General Manager Sandro Rossi received His Holiness, illustrating the center’s distinctive capabilities. CNAO stands out as a unique reality in Italy, remaining one of the very few facilities worldwide capable of delivering hadrontherapy using both protons and carbon ions. The technological core of the facility is its synchrotron, a subatomic particle accelerator that generates ultra-high-precision beams to treat complex, inoperable and radioresistant tumours. This cutting-edge technology allows for the targeted eradication of diseased cells while meticulously preserving surrounding healthy tissues, drastically improving patients’ survival and quality of life.

Furthermore, CNAO is expanding its capabilities as a premier multi-center utilizing new ion species, like Helium, later Oxygen and Neon. Soon, treatments will incorporate the Leo Cancer Care upright positioning and imaging system. The immediate future also includes beginning therapies with a Hitachi dedicated proton accelerator and gantry and a BNCT system for metastatic diseases, equipped with an electrostatic accelerator produced by TAE Life Science. With these new technologies, CNAO will become one of the most technologically advanced center in the world.

To date, over six thousand individuals, including approximately three hundred children and adolescents, have benefited from these life-saving treatments.

During his visit, the Pope engaged with CNAO’s Board of Directors, a collaborative body uniting national universities, clinical institutions, and research centers. He also extended his heartfelt greetings to the two hundred employees of the center. These doctors, physicists, engineers, and researchers tirelessly operate the advanced technologies in the service of oncology patients.

The emotional pinnacle of the day was the Holy Father’s private gathering with a delegation of young children who underwent treatment. The paediatric patients and their families shared a deeply touching moment of closeness, receiving the Pope’s comforting embrace.

“The visit of Pope Leo XIV honours us and represents a moment of extraordinary human value”, stated CNAO President Gianluca Vago. “In his encyclical Magnifica Humanitas, the Holy Father emphasizes the necessity of a science that constantly safeguards the centrality of the person and directs technology toward the common good. In a time marked by global tensions, CNAO testifies daily how the incredible power of the atom can be used not to destroy, but to heal. The particle beams we utilize against disease are, symbolically, Rays of Hope, sharing and supporting the IAEA project bearing this name. The embrace the Holy Father reserved for our children reminds us that scientific research finds its most authentic purpose when it encounters listening, compassion, and hope”.

Photo – https://mma.prnewswire.com/media/2997869/Papa_al_Cnao_crediti_Andrea_Perotti.jpg
Logo – https://mma.prnewswire.com/media/2997643/CNAO_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/pope-leo-xiv-embraces-paediatric-patients-at-cnao-in-pavia-302805799.html

Continue Reading

Technology

HelloNation Article Examines Full Coverage Auto Insurance With Insurance Expert Ben Buenzow

Published

on

By

The article explains what full coverage auto insurance typically includes, what it excludes, and how coverage limits affect Iowa drivers.

URBANDALE, Iowa, June 20, 2026 /PRNewswire/ — What does full coverage auto insurance actually include for drivers in Iowa? That question is answered in a HelloNation article featuring insights from Insurance Expert Ben Buenzow of Buenzow Insurance Group in Urbandale, Iowa.

The HelloNation article explains that full coverage auto insurance is a commonly used phrase that many drivers misunderstand. While the term suggests broad protection, it usually refers to a combination of liability coverage, collision coverage, and comprehensive coverage within an insurance policy. Understanding what these components cover helps drivers avoid gaps in protection and unexpected costs after an accident.

Liability coverage forms the legal foundation of auto insurance in Iowa. The article explains that liability coverage pays for injuries or property damage that a driver causes to others in an accident. State law requires Iowa drivers to carry minimum liability limits, and full coverage auto insurance policies include at least those required limits. However, liability coverage does not pay for damage to the driver’s own vehicle, which is why additional protection is often necessary.

Collision coverage is the part of a policy that helps pay for damage to the driver’s own vehicle after an accident. The HelloNation article notes that collision coverage applies when a vehicle hits another car, a guardrail, or a stationary object. In most cases, the insurer pays the actual cash value of the vehicle or the repair cost minus the policy’s deductible. Insurance Expert Ben Buenzow is featured in the article as a source of insights on how deductibles influence both insurance premiums and out-of-pocket costs during a claim.

Comprehensive coverage addresses a different type of risk. According to the article, comprehensive coverage protects against damage caused by events other than collisions. This includes hail, theft, vandalism, fire, falling objects, or animal-related incidents. For Iowa drivers, weather-related risks such as hailstorms can make comprehensive coverage an important part of a full coverage auto insurance policy.

The HelloNation article also explains that deductibles apply to both collision coverage and comprehensive coverage. The deductible is the amount the policyholder must pay before insurance coverage begins. Drivers can often choose higher or lower deductibles depending on their financial preferences. Higher deductibles typically reduce premium costs but increase the amount paid out of pocket if damage occurs.

Another important takeaway from the article is what full coverage auto insurance does not automatically include. Standard policies usually do not provide roadside assistance, rental reimbursement, or gap coverage unless these features are added separately. The article explains that roadside assistance covers towing or emergency services, while rental reimbursement helps cover the cost of a temporary vehicle during repairs.

Gap coverage is another optional feature highlighted in the article. It is often recommended for drivers who finance or lease newer vehicles. Gap coverage pays the difference between the remaining loan balance and the vehicle’s actual cash value if it is declared a total loss after an accident.

The article also discusses the importance of understanding coverage limits within an insurance policy. Coverage limits determine the maximum amount an insurer will pay for a covered loss. If damage or liability exceeds those limits, the driver may be responsible for the remaining costs. Reviewing coverage limits carefully helps drivers ensure their policy reflects both the value of their vehicle and their financial risk.

Insurance Expert Ben Buenzow is again referenced in the article as part of a broader discussion about how drivers can make informed decisions about Iowa car insurance. The article encourages drivers to evaluate deductibles, coverage limits, and optional protections based on their individual needs.

The HelloNation article concludes by emphasizing that drivers should periodically review their insurance policy. Changes in vehicle value, financial circumstances, and driving habits can all affect the appropriate level of coverage. Understanding the components of full coverage auto insurance helps drivers maintain adequate protection and prepare for unexpected events on the road.

Iowa Auto Insurance: What Full Coverage Includes and Excludes features insights from Ben Buenzow, Insurance Expert of Urbandale, Iowa, in HelloNation.

About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hellonation-article-examines-full-coverage-auto-insurance-with-insurance-expert-ben-buenzow-302805432.html

SOURCE HelloNation

Continue Reading

Trending